Preliminary trials suggest that Retatrutide – a dual agonist of incretin and GIP receptors – offers a considerable breakthrough in body reduction efforts . In contrast to existing medications , this dual-action compound seems to influence food intake and calorie expenditure via multiple pathways . Although further analysis is essential, early f